Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Clinical trial NCT01252940 · COMPLETED
Trial details
- NCT number
- NCT01252940
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2010-11-01
- Primary completion
- 2012-01-01
- Enrollment
- 482
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.